Human VEGFR2/KDR ELISA Kit

Kit Components

 1. Recombinant  Human VEGFR2 standard: 2 vials

 2. One 96-well plate precoated with anti-Human VEGFR2  Ab

 3. Sample diluent buffer: 12 mL - 1

 4. Detection antibody: 130 µL, dilution 1:100

 5. Streptavidin-HRP: 130 µL, dilution 1:100

 6. Antibody diluent buffer: 12 mL x1   

 7. Streptavidin-HRP diluent buffer: 12 mL x1

 8. TMB developing agent: 10 mL x1

9. Stop solution: 10 mL x1.

10. Washing solution (20x): 25 mL x1.

Background

VEGF R2, also known as KDR (kinase insert domain receptor) in humans, Flk-1(fetal liver kinase-1) in mice, protein-tyrosine kinase receptor flk-1, or CD309, is a member of the class III subfamily of receptor tyrosine kinases. The full-length VEGF R2 is a 1356 amino acid (aa) precursor protein composed of a 19 aa signal peptide and an 1335 aa mature protein containing a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. VEGF R1, VEGF R2, and VEGF R3 are preferentially expressed in the proliferating endothelium of vessels lining and/or penetrating solid tumors. VEGF R2, however, is more widely distributed and expressed in all vessel-derived endothelial cells in comparison to VEGF R1.

VEGFR1, VEGFR2 and their derivatives exhibit different capabilities for ligand binding. VEGF R1 binds both PlGF and VEGF with high affinity, VEGF R2 only binds VEGF with high affinity. PlGF/VEGF heterodimers can bind with high affinity to soluble VEGF R2, but PlGF homodimers fail to bind this receptor. Soluble VEGF R2 cannot compete with VEGF for binding to human endothelial cells expressing both VEGF R1 and VEGF R2, in contrast to soluble VEGF R1. Soluble VEGF R2 can only partially inhibit cell migration, whereas soluble VEGF R1 can almost completely block VEGF-induced cell proliferation and migration.